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Data collection and analysis:	Two	reviewers	independently	screened	studies,	extracted	
data,	and	assessed	quality.
Main results:	Eleven	studies	using	a	 range	of	devices	 (condom	catheter,	uterine	suc‐
tion	devices,	Bakri,	 Inpress,	 Ellavi)	were	 identified.	Cost	 of	 condom	catheter	 devices	





Conclusions:	 Evidence	 on	 the	 cost‐effectiveness	 of	 uterine	 tamponade	 devices	 was	
limited	and	not	generalizable.	Rigorous	economic	evaluations	based	on	updated	effect	
estimates	are	needed.
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1  | INTRODUCTION
Obstetric	hemorrhage	is	the	leading	cause	of	maternal	mortality,	con‐
tributing	 to	 27.1%	 (uncertainty	 interval	 19.9%–36.2%)	 of	maternal	
deaths	 worldwide.1	 The	 majority	 of	 these	 are	 postpartum	 hemor‐
rhage	(PPH),	generally	defined	as	blood	loss	of	500	mL	or	more	within	












WHO’s	 2012	 guidelines	 on	 PPH	 prevention	 and	 management	
recommended	that	 if	a	woman	with	PPH	due	to	uterine	atony	does	
not	 respond	 to	 treatment	using	uterotonics	 (i.e.,	 refractory	PPH),	or	
if	 uterotonics	 are	 unavailable,	 then	UBT	 should	 be	 used	 (weak	 rec‐
ommendation,	very‐low‐quality	evidence).5	 In	 this	 situation,	 trained,	
skilled	health	personnel	insert	a	balloon	catheter	inside	the	uterus	that	
(when	 filled)	 applies	 hydrostatic	 pressure	 to	 reduce	 blood	 flow	 and	
facilitate	 clotting.	 In	2019,	 the	WHO	 recommendation	on	UBT	was	
prioritized	for	updating,	in	light	of	new	evidence	regarding	the	balance	
of	risks	and	benefits	of	this	intervention.7,8





device	 type	and	cost.	Even	where	 the	cost	of	using	UBT	 is	high,	 its	
use	 may	 be	 reasonable	 if	 it	 can	 lead	 to	 equally	 large	 health	 gains.	
















2  | MATERIALS AND METHODS
2.1 | Literature search
This	 systematic	 review	was	 conducted	 according	 to	 a	 pre‐specified	
protocol,	 in	 line	with	 the	 Preferred	 Reporting	 Items	 for	 Systematic	
Reviews	and	Meta‐Analyses	(PRISMA)	guidelines	(see	PRISMA	check‐




PubMed	 (January	 1,	 1980	 to	 date	 of	 search),	 EMBASE	 (January	 1,	
1980)	 and	 the	National	Health	 Services	 Economic	 Evaluation	 (NHS	
EED)	database	(inception	in	1995	to	April	2,	2015,	database	closure)	
(search	 strategy	 shown	 in	 File	 S2).	We	 also	 screened	 the	 reference	




studies)	or	effectiveness	 studies	 (such	as	 trials)	 that	provide	 cost	or	
economic	 data.	 Studies	were	 included	 if	 they	 related	 to	 the	 use	 of	




















list,	with	 disagreements	 resolved	 through	 discussion	 or	 consultation	
with	 other	 reviewers	 (see	 File	 S3).16	 All	 extracted	 data	 and	 quality	
assessments	were	reviewed	by	a	health	economist	(NS).
2.3 | Data synthesis
A	conceptual	 framework	was	developed	 to	 clearly	 identify	 the	 role	
and	 possible	 cost	 consequences	 of	 using	 uterine	 tamponade	 in	 the	












3.1 | Characteristics of included studies
In	 total,	573	unique	 records	were	 identified	and	screened,	of	which	
550	were	excluded	at	title	and	abstract	screening	(Fig.	2).	Of	the	23	
full	texts	reviewed,	13	did	not	report	on	relevant	economic	outcomes	





information	 on	 various	 tamponade	 devices.	 Four	 studies	were	 case	








UBT	 purpose‐designed	 devices	 (Every	 Second	Matters	 for	Mothers	
and	 Babies	 (ESM)–UBT	 kit;	 Bakri	 balloon;	 Ellavi;	 Sinapi	 Biomedical,	
Stellenbosch,	South	Africa);	uterine	suction	improvised	devices	(FG36	
Levin	 stomach	 tube);	 and	uterine	 suction	purpose‐designed	devices	
(published	as	Inpress,	subsequently	described	as	the	Jada	System	by	
Alydia	Health	(Menlo	Park,	CA,	USA).29
Studies	 published	 between	 2006	 and	 2019	 quoted	 condom	
catheter	devices	or	kits	 at	US$0.64	 to	US$6,	 though	 in	 the	2017	








were	 significantly	 more	 expensive—Bakri	 balloon	 was	 quoted	 at	
US$250	 to	US$300	 in	 a	 2016	 paper,26	 Inpress	 (Alydia)	 device	 at	
less	than	US$400	in	a	2016	paper,23	and	“commercial	devices”	(not	
otherwise	 specified)	 ranging	 between	 US$125	 and	 US$350	 in	 a	
2017	paper.20
The	 two	 cost‐effectiveness	 studies22,27	 used	 a	 model‐based	
approach	to	estimate	the	incremental	costs	of	introducing	UBT	using	
a	condom	catheter	device	to	treat	PPH	(see	File	S3).	One	was	a	cost‐














and	 reported	 all‐cause	maternal	 survival	 at	 95%.	The	 study	 used	 a	
decision	tree	model,	considered	a	1‐year	time	horizon	for	costs,	and	a	
lifetime	horizon	for	benefits	for	women	receiving	the	intervention	(e.g.	
disability‐adjusted	 life‐years	 [DALYs]	 from	 deaths	 averted),	 did	 not	
include	cost	or	benefit	discounting,	and	performed	multivariate	prob‐








to	hospital.	The	 third	 scenario	 totaled	 an	 additional	US$64,341	per	
F I G U R E  1  Diagram	of	possible	cost	consequences	associated	with	using	uterine	tamponade	in	the	management	of	atonic	postpartum	
hemorrhage.	
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annum	 across	 Kenya	 compared	 with	 the	 base	 case.	 With	 a	 US$5	
price,	 the	analysis	 found	US$26	 incremental	 cost	per	DALY	averted	
(and	less	than	US$41	per	DALY	averted	in	all	sensitivity	analyses),	and	






tries	 only,	 including	 UBT	 (rated	 as	 moderate	 quality	 on	 CHEC).27 
This	 study	 took	a	health	 system	perspective;	however,	 it	 included	




these	 interventions,	 and	univariate	deterministic	 sensitivity	 analy‐




F I G U R E  2  PRISMA	flowchart.	
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against	death	was	assumed	to	be	75%,	referencing	two	case	series	






22	 (81%)	 of	 the	women.32	An	 estimated	 price	 of	 US$6	was	 used	
(condom,	 catheter,	 500	 mL	 saline,	 and	 other	 materials,	 including	
pre‐packaging	and	sterilization).	Costs	were	estimated	for	the	years	
2006,	2010,	and	2015;	equating	to	an	intervention	(and	cost)	time	








Limited	 evidence	 is	 available	 regarding	 the	 cost‐effectiveness	 of	
UBT	 for	 the	 treatment	of	PPH,	 and	no	 cost‐effectiveness	 evidence	
was	found	for	other	tamponade	devices,	such	as	suction	tamponade.	
Some	tamponade	options	cost	between	US$0.64	to	US$6,	including	












their	 longer	time	projections.	The	cost‐effectiveness	of	UBT	 for	 the	
treatment	of	PPH	is	likely	to	vary	across	settings,	depending	on	both	
setting‐specific	 costs	 and	 setting‐specific	 effectiveness	 (which	 may	
vary	because	of	a	range	of	factors	including	healthcare	worker	train‐
ing	and	availability	of	auxiliary	infrastructure	and	equipment).	The	two	
cost‐effectiveness	 analyses	 tested	 the	 sensitivity	 of	 different	 input	
costs,	which	provides	some	insight	into	how	cost‐effectiveness	might	
change	between	settings.	However,	these	studies	either	did	not	under‐























yses	 (mode	of	birth,	 income	 level	of	 countries,	different	 tamponade	
devices)	because	of	limited	data.	Our	review	is	a	systematic	review	of	
available	economic	analyses,	but	is	itself	not	a	cost‐effectiveness	anal‐





efit,	good‐quality	 randomized	 trials	are	 required	 to	establish	 reliable	
estimates	of	benefits	and	harms.	In	the	case	of	UBT,	WHO’s	2012	weak	













favorable	 results.	 Further	 research	 is	 evidently	 required,	 particularly	
the	need	for	robust	cost‐effective	analyses	that	are	based	on	effect	
estimates	derived	from	randomized	trials	of	uterine	tamponade	inter‐
ventions,	 for	 both	 improvised	 and	purpose‐designed	devices.	These	
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